| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MCEE |
| Uniprot No | Q96PE7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 37-176aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMQVTGSVWNLGRLNHVAIAVPDLEKAAAFY KNILGAQVSEAVPLPEHGVSVVFVNLGNTKMELLHPLGRDSPIAGFLQKN KAGGMHHICIEVDNINAAVMDLKKKKIRSLSEEVKIGAHGKPVIFLHPKD CGGVLVELEQA |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
nan
**Background of MCEE Recombinant Protein**
Methylmalonyl-CoA epimerase (MCEE) is a mitochondrial enzyme critical in intermediary metabolism, specifically catalyzing the interconversion of D- and L-methylmalonyl-CoA during propionate catabolism and branched-chain amino acid degradation. This reversible reaction is essential for directing methylmalonyl-CoA into the tricarboxylic acid (TCA) cycle, ensuring energy production and metabolic homeostasis. Genetic mutations in *MCEE* can lead to methylmalonic acidemia, a rare inherited metabolic disorder characterized by the accumulation of toxic metabolites, resulting in neurological and systemic complications.
Recombinant MCEE protein is produced using biotechnological platforms, such as *E. coli* or mammalian expression systems, to express the human *MCEE* gene. This engineered protein retains the enzymatic activity of its native counterpart, enabling its use in functional studies, drug screening, and diagnostic applications. Researchers employ MCEE recombinant protein to investigate enzyme kinetics, substrate specificity, and the structural basis of pathogenic mutations. Additionally, it serves as a tool for developing therapeutic strategies, including enzyme replacement therapies or small-molecule chaperones aimed at restoring metabolic function in affected individuals.
The development of recombinant MCEE also supports advancements in metabolomics and personalized medicine, particularly in understanding genotype-phenotype correlations in methylmalonic acidemia. Its availability facilitates high-throughput assays to identify potential inhibitors or activators, accelerating translational research. Overall, MCEE recombinant protein represents a vital resource for both basic science and clinical innovation, bridging insights into mitochondrial enzymology with therapeutic interventions for metabolic disorders.
×
